中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2009年
9期
974-977
,共4页
刘运秋%李素芹%耿贺梅%刘晓宇
劉運鞦%李素芹%耿賀梅%劉曉宇
류운추%리소근%경하매%류효우
肺癌%胃泌素前体释放肽片断31-98%神经元特异性烯醇化酶%诊断
肺癌%胃泌素前體釋放肽片斷31-98%神經元特異性烯醇化酶%診斷
폐암%위비소전체석방태편단31-98%신경원특이성희순화매%진단
Lung cancer%Pro-gastrin-releasing peptide 31-98%Neuron specific enolase%Diagnosis
目的 探讨血清胃泌素前体释放肽片断31-98(ProGRP)、神经元特异性烯醇化酶(NSE)水平与肺癌不同病理组织学类型的关系及其临床应用价值.方法 将明确病理组织学分型的353例肺癌患者分为2组:小细胞肺癌(SCLC)组96例,非小细胞肺癌(NSCLC)组257例,并以90例肺部良性病变作为对照组,采用酶联免疫吸附实验对所有患者进行血清ProGRP及NSE检测,比较肺癌与肺部良性病变患者之间及不同病理组织学类型肺癌患者之间血清ProGRP、NSE水平其临床应用价值.结果 SCLC组、NSCLC组血清ProGRP、NSE水平均明显高于肺部良性病变组(P均<0.01);血清ProGRP单项检测诊断SCLC的敏感度、特异度、Youden指数和Kappa值,分别为0.7708、0.9444、0.7153和0.7111,血清NSE单项检测诊断SCILC的敏感度、特异度、Youden指数和Kappa值,分别为0.7604、0.8778、0.6382和0.6355;血清ProGRP+NSE联合检测(序列试验)诊断SCLC的敏感度、特异度、Youden指数和Kappa值,分别为0.7604、0.9667、0.7271和0.7221;血清ProGRP+NSE联合检测(平行试验)诊断SCLC的敏感度、特异度、Youden指数和Kappa值,分别为0.8229、0.9000、0.7229和0.7209.血清ProGRP、NSE单项及联合检测诊断NSCLC的敏感度、特异度、Youden指数和Kappa值均较低.结论 在SCLC的诊断中,血清ProGRP检测优于NSE,血清ProGRP+NSE联合检测(平行试验)及ProGRP+NSE联合检测(序列试验)优于血清ProGRP或NSE单项检测,血清Pro-GRP+NSE联合检测(平行试验)优于血清ProGRP+NSE联合检测(序列试验).血清ProGRP及NSE单项及联合检测对NSCLC的诊断价值不大.
目的 探討血清胃泌素前體釋放肽片斷31-98(ProGRP)、神經元特異性烯醇化酶(NSE)水平與肺癌不同病理組織學類型的關繫及其臨床應用價值.方法 將明確病理組織學分型的353例肺癌患者分為2組:小細胞肺癌(SCLC)組96例,非小細胞肺癌(NSCLC)組257例,併以90例肺部良性病變作為對照組,採用酶聯免疫吸附實驗對所有患者進行血清ProGRP及NSE檢測,比較肺癌與肺部良性病變患者之間及不同病理組織學類型肺癌患者之間血清ProGRP、NSE水平其臨床應用價值.結果 SCLC組、NSCLC組血清ProGRP、NSE水平均明顯高于肺部良性病變組(P均<0.01);血清ProGRP單項檢測診斷SCLC的敏感度、特異度、Youden指數和Kappa值,分彆為0.7708、0.9444、0.7153和0.7111,血清NSE單項檢測診斷SCILC的敏感度、特異度、Youden指數和Kappa值,分彆為0.7604、0.8778、0.6382和0.6355;血清ProGRP+NSE聯閤檢測(序列試驗)診斷SCLC的敏感度、特異度、Youden指數和Kappa值,分彆為0.7604、0.9667、0.7271和0.7221;血清ProGRP+NSE聯閤檢測(平行試驗)診斷SCLC的敏感度、特異度、Youden指數和Kappa值,分彆為0.8229、0.9000、0.7229和0.7209.血清ProGRP、NSE單項及聯閤檢測診斷NSCLC的敏感度、特異度、Youden指數和Kappa值均較低.結論 在SCLC的診斷中,血清ProGRP檢測優于NSE,血清ProGRP+NSE聯閤檢測(平行試驗)及ProGRP+NSE聯閤檢測(序列試驗)優于血清ProGRP或NSE單項檢測,血清Pro-GRP+NSE聯閤檢測(平行試驗)優于血清ProGRP+NSE聯閤檢測(序列試驗).血清ProGRP及NSE單項及聯閤檢測對NSCLC的診斷價值不大.
목적 탐토혈청위비소전체석방태편단31-98(ProGRP)、신경원특이성희순화매(NSE)수평여폐암불동병리조직학류형적관계급기림상응용개치.방법 장명학병리조직학분형적353례폐암환자분위2조:소세포폐암(SCLC)조96례,비소세포폐암(NSCLC)조257례,병이90례폐부량성병변작위대조조,채용매련면역흡부실험대소유환자진행혈청ProGRP급NSE검측,비교폐암여폐부량성병변환자지간급불동병리조직학류형폐암환자지간혈청ProGRP、NSE수평기림상응용개치.결과 SCLC조、NSCLC조혈청ProGRP、NSE수평균명현고우폐부량성병변조(P균<0.01);혈청ProGRP단항검측진단SCLC적민감도、특이도、Youden지수화Kappa치,분별위0.7708、0.9444、0.7153화0.7111,혈청NSE단항검측진단SCILC적민감도、특이도、Youden지수화Kappa치,분별위0.7604、0.8778、0.6382화0.6355;혈청ProGRP+NSE연합검측(서렬시험)진단SCLC적민감도、특이도、Youden지수화Kappa치,분별위0.7604、0.9667、0.7271화0.7221;혈청ProGRP+NSE연합검측(평행시험)진단SCLC적민감도、특이도、Youden지수화Kappa치,분별위0.8229、0.9000、0.7229화0.7209.혈청ProGRP、NSE단항급연합검측진단NSCLC적민감도、특이도、Youden지수화Kappa치균교저.결론 재SCLC적진단중,혈청ProGRP검측우우NSE,혈청ProGRP+NSE연합검측(평행시험)급ProGRP+NSE연합검측(서렬시험)우우혈청ProGRP혹NSE단항검측,혈청Pro-GRP+NSE연합검측(평행시험)우우혈청ProGRP+NSE연합검측(서렬시험).혈청ProGRP급NSE단항급연합검측대NSCLC적진단개치불대.
Objective To evaluate the clinical value and relationship between the serum levels of the Pro-gastrin-releasing peptide 31-98 (ProGRP) , neuron-specific enolase NSE and the different pathohistology types of lung cancer. Methods 353 lung cancer patients were divided into two groups according to pathohistology types: SCLC group( n = 96), NSCLC group( n = 257). 90 lung benign lesion were taken as control group. ProGRP and neu-ron specific enolase in all patients were detected by ELISA. The levels of the ProGRP, NSE and the clinical value were compared among lung cancer,lung benign lesion patients and the different pathohistology types of lung cancer patients . Results The levels of the ProGRP and NSE of SCLC and NSCLC group were higher obviously than that of lung benign lesion( P <0.01 ). In SCLC diagnosis, the sensitivity, specificity, Youden index and Kappa value of the ProGRP and NSE were O. 7708,0. 9444,0. 7153,0.7111 and 0. 7604,0. 8778 ,0. 6382 ,0. 6355 in the monomial de-tection ; Those indexes above were 0.7604,0. 9667,0.7271 and 0. 7221 in combined assay of ProGRP + NSE( on se-quence test) ; and were O. 8229,0.9000,0. 7229 and 0. 7209 in combined assay of ProGRP + NSE( on parallell test). In NSCLC diagnosis,the above indexes were all lower. Conclusions in SCLC diagnosis,the detection of the serum ProGRP is superior to the detection of NSE, the combined assay of ProGRP + NSE (on parallell test) and Pro-GRP + NSE( on sequence test) are superior to the monomial detection of the ProGRP or NSE,and the combined as-say of ProGRP + NSE(on parallell test) is superiro to ProGRP + NSE(on sequence test) ; The diagnosis value of the monomial arid united detection of ProGRP and NSE to NSCLC is not as expected.
